Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

New England Journal of Medicine

Volumn 371, Issue 19, 2014, Pages 1771-1780

  Guillevin, Loïc ^a   Pagnoux, Christian ^a,u   Karras, Alexandre ^b   Khouatra, Chahera ^e   Aumaître, Olivier ^g   Cohen, Pascal ^a   Maurier, Franc¸ois ^h   Decaux, Olivier ⁱ   Ninet, Jacques ^f   Gobert, Pierre ^j   Quémeneur, Thomas ^k   Blanchard Delaunay, Claire ^l   Godmer, Pascal ^m   Puéchal, Xavier ^a   Carron, Pierre Louis ⁿ   Hatron, Pierre Yves ^o   Limal, Nicolas ^p   Hamidou, Mohamed ^q   Ducret, Maize ^r   Daugas, Eric ^c   Papo, Thomas ^d   Bonnotte, Bernard ^s,t   Mahr, Alfred ^a   Ravaud, Philippe ^a   Mouthon, Luc ^a   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BICHAT HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Hôpital Universitaire Louis Pradel   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h Department of Surgery   (France)

ⁱ UNIVERSITÉ DE RENNES 1   (France)

^j HÔPITAL DU BOCAGE   (France)

^k CENTRE HOSPITALIER DE VALENCIENNES   (France)

^l Centre Hospitalier de Niort   (France)

^m Centre hospitalier de Bretagne Atlantique   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o UNIV LILLE   (France)

^p HENRI MONDOR HOSPITAL   (France)

^q HÔTEL DIEU   (France)

^r Centre Hospitalier de la Region d'Annecy   (France)

^s DIJON UNIVERSITY HOSPITAL   (France)

^t France   (France)

^u MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANEMIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL ENDOCARDITIS; BASAL CELL CARCINOMA; BLOOD LEVEL; BRONCHITIS; CASE REPORT; CAUSE OF DEATH; CHOLECYSTITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANDIDIASIS; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; INFECTIOUS DIARRHEA; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; OUTCOME ASSESSMENT; PANCREAS CANCER; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROSTATE CANCER; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY DISTRESS; SCORING SYSTEM; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; TUBERCULOSIS; YOUNG ADULT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; KAPLAN MEIER METHOD; MAINTENANCE CHEMOTHERAPY; MULTICENTER STUDY; NEOPLASM; RECURRENT DISEASE;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE;

EID: 84908576790     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404231     Document Type: Article

References (30)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
2. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
3. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
4. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
5. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
6. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
7. Sanders JS, Slot MC, Stegeman CA. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:2072-3.
8. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63:257-66.
9. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27.
10. Clain JM, Specks U. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. Presse Med 2013;42:530-2.
11. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012;64:3770-8.
12. van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
13. Flossmann O, Bacon P, de Groot K, et al. Development of comprehensive disease assessment in systemic vasculitis. Postgrad Med J 2008;84:143-52.
14. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). 2006 (http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf).
15. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:1141-64.
16. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979;301:235-8.
17. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
18. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
19. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68.
20. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-30.
21. Ringelstein M, Harmel J, Distelmaier F, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler 2013;19:1544-7.
22. Pequeño-Luévano M, Villarreal-Martínez L, Jaime-Pérez JC, et al. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases. Hematology 2013;18:233-6.
23. Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol 2013;91:546-51.
24. Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 2014;73:1508-14.
25. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010;62:1166-73.
26. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012;7:240-7.
27. Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 2014;53:1818-24.
28. Hogan J, Avasare R, Radhakrishnan J. Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol 2014;9:1657-67.
29. Springer J, Nutter B, Langford CA, Hoffman GS, Villa-Forte A. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore) 2014;93:82-90.
30. Hoffman GS. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis? Presse Med 2013;42:643-50.